Kornimate/medical-research-clean huggingface dataset:
effectiveness and safety of tdcs for pain

Conditions: Pain, Chronic

Summary: the purpose of this study is to verify the effectiveness and safety of transcranial direct current stimulation in patients with central post-stroke pain.


Eligibility criteria:
inclusion criteria: 1. adults aged 19 to 90 years old 2. those who have been diagnosed with first-time stroke through doctors' clinical observation and brain imaging diagnosis 3. a person whose stroke lesions are cortex or subcortex 4. a person who satisfies 'mandatory criteria' 5. those with cognitive ability to understand and follow the researcher's instructions 6. those who voluntarily agree to participate in this clinical trial and signed the agreement exclusion criteria: 1. those who have a fracture or have undergone orthopedic surgery 2. in case of accompanying serious neurological diseases 3. in case of major psychiatric diseases such as major depression disorders, schizophrenia, bipolar disorders, and dementia 4. those with complex part pain syndrome by budapest criteria 5. if there is a cause of other pain in the relevant area, such as peripheral nerve damage 6. persons included in the exclusion of transcranial direct current stimulation 7. if the researcher is judged to be judged that the participation in this study is not appropriate
blood flow - an underlying mechanism behind clinical improvements in patients with subacromial pain syndrome?

Conditions: Chronic Pain

Summary: the purpose of this randomized clinical trial is two-fold. firstly to see if patients suffering subacromial pain syndrome can improve blood flow in the supraspinatus muscle in their shoulder, and secondly to investigate how changes in this blood flow are related to pain experience and shoulder function.


Eligibility criteria:
inclusion criteria: * shoulder pain for longer than three months * clinical findings indicative of subacromial pain syndrome (evaluated by hawkins-kennedy sign, neers sign, painful arch and yokum test) * normal passive range of motion of the shoulder exclusion criteria: * subjects unable to provide an informed consent * lack of ability to complete the intervention * full rupture of the tendon of m. supraspinatus * planned shoulder surgery, or previous shoulder surgery on affected shoulder * other musculoskeletal problem that could explain the symptoms * adhesive capsulitis * pregnancy * rheumatoid arthritis * symptomatic osteoarthritis of the shoulder/shoulder girdle * glenohumeral instability * widespread pain syndrome * unstable underlying heart disease * cortisone injections in the shoulder the last month * allergies * other serious mental or somatic disease (i.e. psychosis or active cancer disease).

Keywords: shoulder exercise therapy
dolutegravir/lamivudine dual therapy for art-naïve people with hiv and tb receiving rifampin-based tb treatment

Conditions: Tuberculosis; HIV

Summary: this will be a phase iiib clinical trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice daily or dtg/3tc ( dovato) in the morning +dolutegravir (dtg) in the evening, versus standard of care (soc) twice-daily dolutegravir plus 2 once-daily nucleoside reverse-transcriptase inhibitors (nrtis) tenofovir disoproxil fumarate /lamivudine (tdf/3tc), among antiretroviral therapy (art)-nave individuals with hiv-1 receiving rifampin-based tb therapy

tuberculosis (tb) is the most common cause of death in people with hiv worldwide. among patients with hiv, the incidence of tb per year is about 5-10%. the two diseases are now always treated concurrently in co-infected individuals, as there is a survival benefit for starting antiretroviral therapy (art) soon after tb treatment initiation. current brazilian guidelines suggest that for patients with a cluster of differentiation 4 (cd4) \ 50, art should be started within 2 months of starting tb treatment. world health organization guidelines suggest art initiation within 2 weeks of tb diagnosis regardless of cd4 count (provided there are no signs of tb meningitis), but most programs defer art until 6-8 weeks in patients with cd4 \>50 to reduce the risk of immune reconstitution inflammatory syndrome (iris). the option of dual therapy for hiv (i.e., complete regimens to treat hiv composed of only 2 drugs) is of increasing interest and can lower costs for patients, payors, and programs while lowering cumulative lifetime exposure to art (with potential resultant lessened burden of cumulative toxicities) and maintaining high antiviral efficacy. based on the gemini, tango, and salsa clinical trials, a regimen of 50 milligram (mg) dtg combined with 300mg lamivudine (3tc) has been shown to be a highly effective stand-alone option for the treatment of hiv-1 in art treatment-naïve or virologically suppressed individuals through 48 weeks (salsa) and 144 weeks (gemini and tango).

Eligibility criteria:
inclusion criteria: * documentation of hiv-1 status: hiv-1 infection, documented by any licensed rapid hiv test or hiv-1 enzyme or chemiluminescence immunoassay (e/cia) test kit at any time prior to entry and confirmed by a licensed western blot or a second antibody test by a method other than the initial rapid hiv and/or e/cia, or by hiv-1 antigen, or plasma hiv 1 rna viral load. two or more hiv-1 rna viral loads of \>1,000 copies/ml are also acceptable as documentation of hiv-1 infection. * cd4+ cell count ≥50 cells/mm3 obtained within 30 days prior to study entry * hiv-1 viral load ≥1000 copies/ml * art-naïve. * documentation of pulmonary tb exclusion criteria: * pregnant, or plans to become pregnant.
fearless in cognitively intact patients with glioma

Conditions: Glioma; Fear of Cancer

Summary: this study will assess the preliminary feasibility and acceptability of fearless, a newly-developed psychological intervention for fear of cancer recurrence (fcr) among cognitively-intact patients with glioma.


Eligibility criteria:
inclusion criteria: patient inclusion: * confirmed glioma diagnosis (grade ii-iv) via histopathology * be a minimum of 2 weeks post surgical repair or biopsy (if applicable) * elevated fcr \[\> 13 on fear of cancer recurrence inventory\] * primarily english speaking caregiver inclusion: * loved one, or non-paid care partner to a patient with a confirmed glioma diagnosis (grade ii-iv) via histopathology * elevated fcr \[\> 13 on fear of cancer recurrence inventory\] * primarily english speaking * age 18+ exclusion criteria: patient: * cognitive impairment \[\< or equal to 31 on the telephone interview for cognitive status (tics)\] * inability to attend virtual sessions (e.g. due to lack of stable internet connection, difficulty using technology) * inability to understand and provide informed consent. caregiver: * inability to attend virtual sessions (e.g. due to lack of stable internet connection, difficulty using technology) * inability to understand and provide informed consent.
response of bony metastasis to tyrosine kinase inhibitors in non-small cell lung cancers with actionable driver mutations.

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to assess percentage reduction in the of urine ntx and serum ctx , in patients with nsclc and bone metastases 1) with actionable driver oncogene on standard of care (soc) tki at 3 months post treatment and 2) without actionable mutations on standard of care therapy (chemotherapy/immunotherapy) treated with zoledronic acid or denosumab at the same time period.

this is an observational study involving two arms of nsclc with metastatic bony disease at the time of enrollment in the study. one group will have an actionable driver oncogene and initiate treatment in any line with a tki as standard of care and concurrent to participation to this study; expected to have an objective response rate in ≥40% who have not previously seen anti-bone resorptive therapy. the other group will not have actionable mutations and initiate treatment with chemotherapy/immunotherapy along with new onset therapy with iv zoledronic acid 4mg q4 weeks or subcutaneous denosumab 120 mg q12 weeks for bone disease, which is standard of care and would be concurrent to participation in this study. baseline and on-treatment imaging and serum total alkaline phosphatase will be performed per soc. additional non-soc bone turnover markers including , urine n-telopeptide (ntx) and serum c-terminal telopeptide (ctx), will be checked at baseline and then at 1, 3, 6, and 12 months.

Eligibility criteria:
inclusion criteria: 1. provision to sign and date the consent form 2. stated willingness to comply with all study procedures and be available for the duration of the study 3. be a male or female aged 18-100 years 4. pathologically confirmed non-small cell lung cancer 5. molecular testing through a clia-validated ngs assay. this can be done using either tissue based samples or blood-based samples (ctdna) 6. ecog ps 0-2 7. decision to be on a particular standard of care tki or chemotherapy +/- immunotherapy (clinical decision that would occur prior to study enrollment) 8. patients who will be treated with an osteoclast inhibitor must receive dental clearance prior to starting treatment 9. bone metastases must be detected through radiographic imaging prior to enrollment on this study. exclusion criteria: 1. actionable driver mutation nsclc patient who has been on anti-bone resorptive therapy a. excluded anti-bone resorptive therapy includes: zolendronic acid, pamidronate, alendronate, denosumab or any medication that acts as an osteoclast inhibitor 2. have any condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with evaluation while on standard of care treatments for the nsclc. 3. patients with actionable driver mutation who received tki in past or currently on tki prior to screening 4. bone metastases that have received prior radiotherapy unless unequivocal progression has occurred since radiation therapy
combination of chemotherapy plus rt and shr-1210 to treat patients with escc

Conditions: Esophageal Cancer

Summary: shr-1210 is a humanized anti-pd1 igg4 monoclonal antibody. this is an openlabel，single center ，non-randomized ，single arm exploratory study . this clinical study is an investigator-initiated clinical trial（iit). the objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-pd-1 antibody shr-1210 and chemotherapy in patients with locally advanced esophageal squamous cell carcinomas。


Eligibility criteria:
inclusion criteria: 1. age:18-75 years, male or female. 2. histologically confirmed primary squamous cell carcinoma of the esophagus,local advanced esophageal cancer diagnosed by pathology and imaging,clinical stage t3-4n0m0, t1-4n+m0,ⅱ-ⅳa. 3. pre-treatment evaluation can not tolerate concurrent radiochemotherapy or rejection of the concurrent use of chemotherapy with radiotherapy. 4. measurable disease based on response evaluation criteria in solid tumors (recist) 1.1. 5. ecog 0-1. 6. adequate organ function. 7. life expectancy of greater than 6 months. 8. patient has given written informed consent. exclusion criteria: 1. patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy. 2. known history of hypersensitivity to macromolecular protein preparation or any components of the shr- 1210 formulation. 3. subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ); 4. subjects with any active autoimmune disease or history of autoimmune disease - page 4 of 4 \[draft\] - 5. uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> nyha ii congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention; 6. active infection or an unexplained fever \> 38.5°c during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator); 7. received a live vaccine within 4 weeks of the first dose of study medication. 8. pregnancy or breast feeding. 9. decision of unsuitableness by principal investigator or physician-incharge.

Keywords: esophageal cancer concurrent chemoradiation immunotherapy shr-1210 apatinib
adverse events for free flap surgery in head and neck cancer

Conditions: Surgical Flaps; Flap Failure Risk Factors; Hematoma Risk Factors; Thrombosis Risk Factors

Summary: this is a cohort study collecting patients with head and neck cancer who underwent free flap surgery at a single medical center between january 2019 and january 2022.

patient information are collected from the electronic medical records retrospectively: head and neck cancer diagnosis: the international classification of diseases, tenth revision (icd-10), which included c00-c14, c31, c32, c73, c75.0, c75.4 and c41.1. the cancer stage, alcohol use, betel nut, and smoking, and baseline comorbidities. surgical characteristics including flap history, ablation time, reconstruction time, donor sites, recipient sites, neck dissection, flap size, anastomosis, artery types, vein types, intraoperative sealants used, and intravenous calcium channel blocker nicardipine to control hypertension after surgery.

Eligibility criteria:
inclusion criteria: * age greater and equal to 20 years old * underwent free flap surgery * had head and neck cancer exclusion criteria: * hiv positive * pregnant, breast feeing women * missing surgical charts
deswt-pilot study on the safety of myocardial regeneration by direct epicardial shock wave therapy in combination with coronary artery bypass grafting

Conditions: Reduced Left Ventricular Function Defined as LVEF < 50%; Regional Left Ventricular Wall Motion Abnormalities

Summary: study purpose: to examine the safety of myocardial regeneration by direct epicardial shock wave therapy in combination with coronary artery bypass grafting.

direct epicardial shock wave therapy: deswt will be performed in adjunct to a standard cabg procedure. prior to aortic cross clamping, deswt will be performed using a cardiogold® cg050 (crt cardiac regeneration technologies, woodstock, usa / manufactured by mts-europe gmbh, konstanz, germany) shock wave therapy device and a specially designed handheld applicator under sterile conditions. depending on the localisation of the myocardial infarct scar, 290-310 impulses will be applied to the anterior, lateral, or posterior wall. shock waves will be generated at 1 or 2 hz in a non ecg triggered fashion, should deswt result in significant ventricular arrhythmias, ecg gating will be initiated. after completion of deswt, cabg will be continued in a regular fashion.

Eligibility criteria:
inclusion criteria: * male or female patients above 18 years of age undergoing primary coronary artery bypass grafting. * patients have to present with reduced left ventricular function defined as lvef \< 50%. * patients have to present with regional left ventricular wall motion abnormalities. * patients have to give written informed consent to participate in the study. exclusion criteria: * significant concomitant valve disease(except significant valve disease not detected in preoperative cardiac ultrasound that is detected intra-operatively). * hiv positive patients. * hepatitis c positive patients. * patients in cardiogenic shock. * patients with a contraindication for cardiac mri. * present contraindication for transoesophageal echocardiography (tee). * history of significant ventricular arrhythmias, except arrhythmias associated with mi. * highly reduced left ventricular function defined as lvef \<30%. * present co-morbidity which reduces life expectancy to less than 6 months. * presence of ventricular thrombus. * presence of a cardiac tumor. * pregnancy.

Keywords: coronary artery bypass grafting myocardial regeneration
dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy

Conditions: Breast Cancer; Skin Reactions Secondary to Radiation Therapy

Summary: this pilot clinical trial studies dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy. radiation dermatitis is a skin condition in which the affected skin becomes painful, red, itchy, and blistered. dakin's solution may help reduce dermatitis caused by radiation therapy.

primary objectives: i. to determine the percent change in women who experience grade 3 or 4 radiation dermatitis as defined by the stanford radiation dermatitis scoring system during radiation treatment for breast cancer compared to historical experience using standard skin care. secondary objectives: i. to assess the feasibility of daily application of the hypochlorite solution (dakin's solution), and to assess levels of pain during radiotherapy treatment. outline: patients apply dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks. after completion of study treatment, patients are followed up at 4-6 weeks.

Eligibility criteria:
inclusion criteria: * women with breast cancer who plan to undergo radiation therapy to the breast or chest wall * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * women with scleroderma or discoid lupus * women with inflammatory breast cancer as evidenced by clinical assessment * women with breast cancer involving the skin * women who have undergone prior radiotherapy to the chest wall and/or breast
understanding patient engagement trends in anxiety disorder clinical research

Conditions: Anxiety Disorder

Summary: clinical trials, specifically focused on anxiety disorder, are crucial in assessing the safety and efficacy of new treatments. these trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. the main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * diagnosis of anxiety disorder * able to comprehend the investigational nature of the protocol and provide informed consent exclusion criteria: * female patients who are currently pregnant or nursing * has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * inability to perform regular electronic reporting

Keywords: anxiety disorder
to demonstrate the relative bioavailability study of ramipril 10 mg capsules under fasting conditions

Conditions: Hypertension

Summary: to demonstrate the relative bioavailability study of ramipril 10 mg capsules under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.
non-cancer pain and cognitive impairment: a disabling relationship

Conditions: Arthritis; Pain; Cognitive Impairment

Summary: to compare the efficacy of long-acting oxycodone to extended-release acetaminophen in older persons with no and mild to moderate cognitive impairment and persistent moderate or higher intensity non-cancer lower extremity arthritis pain; and describe the association of change in non-cancer pain self-report with an older adults functional status (bpi and womac and brief physical performance measure) and to determine if cognitive status modifies this relationship.


Eligibility criteria:
inclusion criteria: 1. age over 65 2. pain at least 3 months duration 3. pain greater in lower extremity than other anatomical site with ambulation 4. pain self-report of moderate intensity of higher on an average day 5. community-dwelling 6. ambulatory 7. physician states participants have decision-making capacity to enroll into the trial 8. participants with cognitive impairment have a reliable caregiver 9. inadequate pain relief from nsaids and/or acetaminophen in the past exclusion criteria: 1. current cancer requiring chemotherapy 2. history of addiction to opioids or other controlled substance 3. consumes more than 2 alcoholic drinks a day 4. severe balance disturbance 5. intra-articular steroid injection in the past 6 weeks

Keywords: pain analgesia cognitive impairment randomized controlled trial physical function
innovation for standard identification of insertional hpv mutations and of target therapeutic genes in cervical cancer: towards development of personalized biomarkers in clinical oncology

Conditions: Cervical Cancer

Summary: quantification and follow-up of circulating tumoral dna in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.

quantification and follow-up of circulating tumoral dna in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.

Eligibility criteria:
inclusion criteria: 1. patient with cervical cancer, at any stage, before any anti-tumoral treatment. 2. age ≥ 18 years. 3. patient information and signature of the informed consent or her/his legal representative. 4. patient having given her/his agreement for a second biopsy at diagnosis if the first one was performed outside of the center and was not cryopreserved. exclusion criteria: 1. person deprived of liberty or under supervision. 2. inability to attend scheduled follow-up visits for any psychological, sociological or geographical reasons.

Keywords: patients with cervical cancer
therapy of pain syndromes according to mcgill's method in physiotherapy

Conditions: Vertebrogenic Pain Syndrome

Summary: the goal of this study is to determine the applicability of mcgill ́s method to patients with diagnoses, collectively referred to as vertebrogenic algic syndrome, by comparing the measured data of proband with different diagnosis locations vertebrogenic algic syndrome in the czech republic.

this is a pilot experimental research involving 10 probands diagnosed with vertebrogenic algic syndrome in the cervical spine, 10 probands diagnosed with vertebrogenic algic syndrome in the thoracic spine and 10 probands diagnosed with vertebrogenic algic syndrome in the lumbar spine. each participant undergo a kinesiological examination according to the mcgill ́s principles together with an sf-36 questionnaire. measured values are compared and provided a basis for testing the hypotheses. the study uses methods of research, observation, querying and comparison of collected data.

Eligibility criteria:
inclusion criteria: * cervical pain syndrome * thoracic pain syndrome * lumbar pain syndrome exclusion criteria: * red falgs

Keywords: pain syndrome efficiency stabilization mcgill method